Lantheus Holdings reported revenue growth for the company's third quarter of fiscal 2021, but the company's net loss more than doubled.
For the period (end-September 30), the company said its revenue for the quarter was $102.1 million, an increase of 15.3% from the previous year when it posted sales of $88.5 million. The firm's net loss under generally accepted accounting principles (GAAP) was $13.4 million for the quarter, compared with a net loss of $6.4 million in the previous year.
Lantheus said the revenue growth can be attributed to adoption of its Pylarify prostate-specific member antigen (PSMA) PET imaging agent, as well as continued growth of its Definity and TechneLite products. Lantheus will also continue its ongoing Arrow phase II study of 1095, a PSMA-targeted therapeutic.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
